FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell Therapy to Grow Heart Muscle in Children With Congenital Heart Disease

http://ift.tt/eA8V8J

BOSTON, NEW YORK, and MELBOURNE, Australia, April 03, 2017 (GLOBE NEWSWIRE) — Boston Children’s Hospital, the pediatric teaching hospital of Harvard University, and Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the United States Food and Drug Administration (FDA) has cleared the commencement of a 24-patient trial combining Mesoblast’s proprietary allogeneic mesenchymal precursor cells (MPCs) with ...

The post FDA Clears Heart Disease Trial at Harvard's Boston Children’s Hospital Using Mesoblast's Cell Therapy to Grow Heart Muscle in Children With Congenital Heart Disease appeared first on ForexTV.

April 04, 2017 at 02:01AM

http://ift.tt/2ouSnGv

from Nasdaq NewsFeed

http://ift.tt/2ouSnGv